6 articles, transcripts, and reports
Alexion Pharmaceuticals Inc (ALXN) Q1 2020 earnings call dated May. 06, 2020 Corporate Participants: Chris Stevo — Head of Investor Relations Ludwig Hantson — Chief Executive Officer Aradhana Sarin — Executive…
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) reported its financial results for the quarter ended March 31, 2020, on Wednesday before the market opens. The results exceeded…
Alexion Pharmaceuticals (NASDAQ: ALXN) announced today that it will be acquiring commercial-stage biopharmaceutical company Portola Pharmaceuticals (NASDAQ: PTLA) for an initial consideration of $1.44 billion…
Alexion Pharmaceuticals Inc (NASDAQ: ALXN) Q4 2019 Earnings Conference Call January 30, 2020 Corporate Participants: Morgan Sanford — Director of Investor Relations Ludwig Hantson — Chief Executive Officer Aradhana Sarin — Executive…
— Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) reported earnings of $2.71 per share in the fourth-quarter 2019, vs. $2.60 per share expected. — Total revenue rose…
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) reported third-quarter 2019 earnings of $2.79 per share, vs. $2.47 per share expected. Revenues grew 23% to $1.26 billion, vs.…
